Salud financiera de hoja de balance de Lipocine

Salud financiera controles de criterios 6/6

Lipocine tiene un patrimonio de los accionistas total de $20.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $23.0M y $2.6M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$22.04m
Patrimonio	US$20.37m
Total pasivo	US$2.63m
Activos totales	US$23.00m

Actualizaciones recientes sobre salud financiera

Recent updates

Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%

Sep 26

Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

Feb 22

Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

Sep 14

Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression

Jun 14

Lipocine competitor prevails in patent infringement lawsuit for Jatenzo

May 26

When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

May 11

Lipocine EPS beats by $0.01

May 06

Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

Jan 26

Lipocine announces positive results from phase 2biopsy-confirmed NASH study

Jan 12

FDA Ok's Lipocine's testosterone replacement therapy, tentatively

Dec 09

Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Dec 04

Lipocine EPS misses by $0.01

Nov 10

Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection

Nov 06

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($22.9M) de LPCN superan a sus pasivos a corto plazo ($2.6M).

Pasivo a largo plazo: LPCN no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: LPCN está libre de deudas.

Reducción de la deuda: LPCN no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 108.8%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: LPCN tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: LPCN dispone de suficiente cash runway para 1.4 años si el flujo de caja libre sigue creciendo a tasas históricas de 8.2% cada año.

Salud financiera de hoja de balance de Lipocine

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Lipocine Receives Non-Compliance Letter from Nasdaq Regarding an Additional 180-Day Grace Period

Lipocine Receives Non-Compliance Letter from Nasdaq

Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Lipocine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Recent updates

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Inc., Annual General Meeting, Jun 05, 2024

Lipocine Inc. Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Inc. Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Price target decreased by 13% to US$33.00

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

New minor risk - Share price stability

Consensus EPS estimates fall by 27%

New major risk - Revenue and earnings growth

Lipocine Inc. Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

New minor risk - Shareholder dilution

Lipocine Inc. Announces Positive Topline Results from A Phase 2 Clinical Study of LPCN 1148

Consensus revenue estimates fall by 60%

Consensus revenue estimates fall by 20%

Lipocine Inc. Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis

Lipocine Receives Non-Compliance Letter from Nasdaq Regarding an Additional 180-Day Grace Period

Price target increased to US$3.83

Price target increased to US$3.83

Lipocine Inc. Announces Senior Leadership Appointments to Advance Its CNS-Focused Pipeline

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)

Price target decreased to US$3.33

Lipocine Inc. Announces U.S. Food and Drug Administration Accept Its Investigational New Drug Application

Lipocine Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 67%

Lipocine Inc. Announces Positive LPCN 1144 Nash Open Label Extension Study Results

Price target decreased to US$3.83

Insufficient new directors

Lipocine Inc., Annual General Meeting, Jun 08, 2022

Lipocine Inc. Announces Board Appointments

Lipocine Inc. Announces Its Partner Received FDA Approval of TLANDO™

Consensus forecasts updated

Lipocine Inc. Announces Regulatory Guidance on LPCN 1144 in Non-Cirrhotic Nash

Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

Lipocine Inc. Announces Peer-Reviewed Publication of Positive Phase 3 Study Results for TLANDO

Lipocine Inc. Announces Patient Dosed in its Phase 2 Study with LPCN 1148 for Management of Liver Cirrhosis

No longer forecast to breakeven

Price target decreased to US$3.75

Lipocine Inc. Announces FDA Affirmation of Class 1 NDA Resubmission for Tlando®

Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

Lipocine Inc. Announces Positive Topline 36-Week Results from Phase 2 Proof of Concept Lift

No longer forecast to breakeven

Consensus forecasts updated

Lipocine Inc. Enters into Global Settlement and License Agreement with Clarus Therapeutics Inc. to Resolve All Outstanding Claims in On-Going Intellectual Property Litigation and Interference Proceeding

Price target decreased to US$4.50

Lipocine Inc. Announces U.S. Food and Drug Administration Clears Investigational New Drug Application to Initiate A Phase 2 Study to Evaluate the Therapeutic Potential of LPCN 1154

Lead Independent Director Stephen Hill has left the company

Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression

Clarus Therapeutics Defeats Lipocine's Patent Infringement Lawsuit On Summary Judgment

Lipocine competitor prevails in patent infringement lawsuit for Jatenzo

When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

Lipocine EPS beats by $0.01

Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

New 90-day high: US$1.76

Lipocine Inc. Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

Lipocine Inc. Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed Nash Subjects

Lipocine announces positive results from phase 2biopsy-confirmed NASH study

Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study

Price target raised to US$5.33

Lipocine Announces Tentative Approval of Tlando™

FDA Ok's Lipocine's testosterone replacement therapy, tentatively

Co-Founder exercised options and sold US$68k worth of stock

New 90-day high: US$1.69

Lipocine Provides New Regulatory Update on TLANDO™

Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Earnings beat expectations

Lipocine EPS misses by $0.01